The EMA has initiated the rolling review, the continuous review of clinical data, of the anti-Covid vaccine Vidprevtyn, developed by Sanofi Pasteur. The EU agency reports this via social media. The vaccine experimentation had not initially given satisfactory results and the process had stopped. Now the EMA Committee for Medicinal Products for Human Use (CHMP) has decided to launch the ongoing review based on non-clinical laboratory data and clinical trials in adults, which “suggest” that the vaccine stimulates production of antibodies against Sars-CoV-2, and which “could”, therefore, protect against Covid-19, the disease caused by the virus. The rolling review, continues the European Medicines Agency, “will continue until they are available sufficient evidence “to apply for conditional authorization for marketing in the EU. Sanofi’s vaccine is protein-based: it contains a lab-grown version of the ‘spike’ protein, the one that allows the virus to enter human cells, and also an adjuvant, a substance that helps boost the immune system’s response to the vaccine. When a person receives the vaccine, their immune system recognizes the ‘spike’ protein as foreign and creates antibodies against it. If, later, the same person comes into contact with Sars-CoV-2, the immune system recognizes the ‘spike’ protein and is therefore able to protect the vaccinated from the virus.